[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP034815A - "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas" - Google Patents

"composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"

Info

Publication number
ECSP034815A
ECSP034815A EC2003004815A ECSP034815A ECSP034815A EC SP034815 A ECSP034815 A EC SP034815A EC 2003004815 A EC2003004815 A EC 2003004815A EC SP034815 A ECSP034815 A EC SP034815A EC SP034815 A ECSP034815 A EC SP034815A
Authority
EC
Ecuador
Prior art keywords
methods
compositions
timolol
ocular hypertension
hypotensive
Prior art date
Application number
EC2003004815A
Other languages
English (en)
Inventor
Alexander Kharlamb
David F Woodward
June Chen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23135192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP034815(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ECSP034815A publication Critical patent/ECSP034815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Nuevas composiciones y métodos para tratar la hipertensión ocular proporcionan el tratamiento efectivo de la hipertensión ocular utilizando, a menudo concentraciones reducidas de componentes activos. Tales composiciones incluyen un componente de timolol y un componente lípido hipotensor. Las presentes composiciones y los métodos son relativamente directos, pueden ser fácilmente producidos , por ejemplo, utilizando las técnicas de fabricación convencional y pueden ser fácil y convencionalmente practicados, por ejemplo, utilizando las técnicas o metodologías de aplicación o administración que son substancialmente similares a aquellas empleadas con las composiciones anteriores utilizadas para tratar la hipertensión ocular.
EC2003004815A 2001-05-31 2003-10-20 "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas" ECSP034815A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29484501P 2001-05-31 2001-05-31

Publications (1)

Publication Number Publication Date
ECSP034815A true ECSP034815A (es) 2004-07-23

Family

ID=23135192

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004815A ECSP034815A (es) 2001-05-31 2003-10-20 "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"

Country Status (21)

Country Link
US (5) US8629140B2 (es)
EP (2) EP1392319B1 (es)
JP (2) JP4475871B2 (es)
KR (1) KR100891266B1 (es)
CN (1) CN100391461C (es)
AR (1) AR035248A1 (es)
AT (1) ATE506066T1 (es)
AU (1) AU2002312221B2 (es)
BR (1) BR0209709A (es)
CA (1) CA2445386C (es)
CY (1) CY1111872T1 (es)
DE (1) DE60239797D1 (es)
DK (1) DK1392319T3 (es)
EC (1) ECSP034815A (es)
ES (1) ES2363077T3 (es)
HK (1) HK1070830A1 (es)
MX (1) MXPA03010146A (es)
NZ (1) NZ528998A (es)
PT (1) PT1392319E (es)
TW (1) TWI298257B (es)
WO (1) WO2002096432A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
ATE444732T1 (de) 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
CA2553381C (en) 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
BRPI0513243B8 (pt) * 2004-07-12 2021-05-25 Allergan Inc composições oftálmicas e respectivos usos
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
AR076731A1 (es) * 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
WO2011057129A2 (en) 2009-11-09 2011-05-12 Allergan, Inc. Compositions and methods for stimulating hair growth
PL2547323T3 (pl) 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
ES2708451T3 (es) 2010-07-29 2019-04-09 Allergan Inc Soluciones de bimatoprost y timolol sin conservantes
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
CA2837240A1 (en) * 2011-05-27 2012-12-06 Ratiopharm Gmbh Ophthalmic preparation comprising a pgf2.alpha. analogue
EP2841104A1 (en) 2012-04-24 2015-03-04 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
US20140234389A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
WO2019063551A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF OCULAR DISEASES
JP7353292B2 (ja) 2018-03-02 2023-09-29 ノバリック ゲーエムベーハー ネビボロールを含む医薬組成物
WO2019185543A1 (en) * 2018-03-28 2019-10-03 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP4406533A3 (en) 2018-10-12 2024-10-09 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
CN112933096B (zh) * 2019-12-11 2023-06-13 中国科学院上海药物研究所 丁酰噻吗洛尔在制备治疗浅表型、混合型或深部血管瘤的药物中的用途
US12042502B2 (en) 2022-03-21 2024-07-23 Somerset Therapeutics, Llc Enhanced penetration ophthalmic compositions of bimatoprost and timolol

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (de) * 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
US5554367A (en) 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
DE3871596T3 (de) 1987-04-03 2000-09-07 Pharmacia & Upjohn Ab, Stockholm Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.
US4952581A (en) * 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
EP1348437A3 (en) 1988-09-06 2003-11-19 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
ES2084771T3 (es) 1990-05-22 1996-05-16 R Tech Ueno Ltd Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica.
SG84487A1 (en) * 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
RO113612B1 (ro) 1991-04-17 1998-09-30 Merck & Co Inc Compozitie oftalmica
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
US5268624A (en) * 1992-10-14 1993-12-07 Allergan, Inc. Foot pedal control with user-selectable operational ranges
US6184250B1 (en) * 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
EP1057486A1 (en) 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Use of drug combination for treating Glaucoma
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
JP2002521332A (ja) 1998-07-21 2002-07-16 メルク エンド カムパニー インコーポレーテッド 高眼圧治療用眼薬組成物
CA2368242A1 (en) 1999-03-12 2000-09-21 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US20030018079A1 (en) 2000-11-13 2003-01-23 Richardson Helene Treatment
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same

Also Published As

Publication number Publication date
JP2004532870A (ja) 2004-10-28
KR20040007577A (ko) 2004-01-24
PT1392319E (pt) 2011-06-28
BR0209709A (pt) 2004-07-27
DE60239797D1 (de) 2011-06-01
MXPA03010146A (es) 2004-03-10
US20170112853A1 (en) 2017-04-27
US8906907B2 (en) 2014-12-09
AR035248A1 (es) 2004-05-05
US8618093B2 (en) 2013-12-31
US20150150880A1 (en) 2015-06-04
US20030069286A1 (en) 2003-04-10
WO2002096432A3 (en) 2003-05-08
ES2363077T3 (es) 2011-07-20
JP2010031041A (ja) 2010-02-12
EP2272518A1 (en) 2011-01-12
JP4475871B2 (ja) 2010-06-09
CA2445386A1 (en) 2002-12-05
US20140051704A1 (en) 2014-02-20
KR100891266B1 (ko) 2009-03-30
CY1111872T1 (el) 2015-11-04
TWI298257B (en) 2008-07-01
US9474760B2 (en) 2016-10-25
CN1543348A (zh) 2004-11-03
EP1392319B1 (en) 2011-04-20
ATE506066T1 (de) 2011-05-15
CN100391461C (zh) 2008-06-04
EP1392319A2 (en) 2004-03-03
WO2002096432A2 (en) 2002-12-05
NZ528998A (en) 2005-06-24
DK1392319T3 (da) 2011-06-27
US10045997B2 (en) 2018-08-14
AU2002312221B2 (en) 2007-02-15
CA2445386C (en) 2010-08-24
US20090181969A1 (en) 2009-07-16
US8629140B2 (en) 2014-01-14
HK1070830A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
PL396553A1 (pl) Zastosowanie czynnika do wytwarzania leku do leczenia jaskry
BR0317891A (pt) Tratamento de ferimentos de pele usando polienilfosfatidil colina e alcanolaminas
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
ATE347353T1 (de) Verwendung von einem östrogen agonist/antagonist zur behandlung der weiblichen sexuellen störungen
DK1553953T3 (da) Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom
ES2193901T1 (es) Derivados de prostaglandina para el tratamiento de glaucoma o hipertension ocular.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
AR039416A1 (es) Un metodo para prevenir y/o tratar el rechazo cronico en un organo o un tejido transplantado
DE60315964D1 (de) Verbesserung der herstellung von endogenen gonadotropin
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
EA200500804A1 (ru) Топические противоинфекционные композиции
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
FR2754712B1 (fr) Compositions ophtalmiques
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
BR9907715A (pt) Composição oftálmica/método para tratamento de lesão córnea e/ou de estesia córnea deteriordada, sìndrome de olho seco, hipolarcrimação e uso de um inibidor de redutase de aldose
BR0317095A (pt) Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
AR013163A1 (es) Uso de composiciones que contienen diclorofenil imidazoldioxolano para la preparacion de un medicamento para tratar la dermatitis seborreica, caspa,psoriasis y acne, composiciones propiamente dichas, y un articulo de fabricacion que contiene dicha composicion
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
ES2139602T3 (es) Composiciones oculares que contienen esteroides y su utilizacion para el tratamiento del glaucoma.
ATE359774T1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen